Maximilian von Eynatten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maximilian von Eynatten has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Peter P. Nawroth
Department of Medicine I and Clinical Chemistry and Medicine III, Heidelberg University, Im Neuenheimer Feld, Heidelberg, Germany
3 shared publicationsAndreas Hamann
Department of Medicine I and Clinical Chemistry , Ruprecht-Karls-University of Heidelberg , Germany
2 shared publicationsAngelika Bierhaus
Department of Medicine I and Clinical Chemistry and Medicine III, Heidelberg University, Im Neuenheimer Feld, Heidelberg, Germany
2 shared publicationsBruno Allolio
Department of Medicine I, Wuerzburg University, Josef-Schneider-Str.2, Wuerzburg, Germany
2 shared publicationsD. Liu
Department of Nephrology, Technische Universitaet Muenchen, Munich, Germany
2 shared publications- Hermann Brenner
Cancer Prevention Graduate School, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
2 shared publications
Latest Publications
- Open Access
- 1 January 2010
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 9 (1) , 48
Associations of Fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy
Ambigous results exist on fetuin-A as marker for vascular disease in type 2 diabetes. This study aims to define the role of fetuin-A as marker for micro- and macrovascular disease in a high risk population of patients with type 2 diabetes mellitus and early diabetic nephropathy.
- 1 January 2010
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 9 (1) , 48
Open AccessAssociations of Fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy
Ambigous results exist on fetuin-A as marker for vascular disease in type 2 diabetes. This study aims to define the role of fetuin-A as marker for micro- and macrovascular disease in a high risk population of patients with type 2 diabetes mellitus and early diabetic nephropathy.
- 10 June 2009
- Published by Wiley in Clinical Endocrinology
- Vol. 71 (1) , 27-32
Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes
Objective Multimeric high molecular weight (HMW) forms of adiponectin were previously shown to be inversely associated with the extent of atherosclerosis in males and are down‐regulated in patients with the metabolic syndrome and type 2 diabetes. In this study, potential influences of atorvastatin therapy on adiponectin multimer distribution were studied in patients with type 2 diabetes. Design, patients and measurements The effect of 40 mg atorvastatin on HMW, medium molecular weight (MMW), and low molecular weight (LMW) isoforms of adiponectin were investigated in 75 patients (23 females; 52 males) with type 2 diabetes in an 8‐week‐long, placebo‐controlled and randomized study. Adiponectin multimeric isoforms were detected by Western blot analysis. Results After atorvastatin therapy the median serum concentration of HMW adiponectin increased significantly by 42·3% (1·68 vs. 2·39 µg/ml; P < 0·001), while concentrations of MMW adiponectin and LMW adiponectin significantly decreased by 20·8% and 23·2%, respectively (MMW: 3·31 vs. 2·62 µg/ml, P = 0·047; LMW: 0·56 vs. 0·43 µg/ml, P = 0·033). Median total adiponectin levels were not significantly altered by atorvastatin treatment (6·0 vs. 6·2 µg/ml, P = 0·898). Consequently, the HMW : total‐adiponectin ratio significantly increased by 25·0% (0·40 vs. 0·50; P = 0·013). Conclusions Atorvastatin therapy is associated with significant changes in adiponectin multimer distribution in patients with type 2 diabetes. Since total adiponectin levels were not affected by intervention, atorvastatin may shift adiponectin size towards the HMW form.
- 10 June 2009
- Published by Wiley in Clinical Endocrinology
- Vol. 71 (1) , 27-32
Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes
Objective Multimeric high molecular weight (HMW) forms of adiponectin were previously shown to be inversely associated with the extent of atherosclerosis in males and are down‐regulated in patients with the metabolic syndrome and type 2 diabetes. In this study, potential influences of atorvastatin therapy on adiponectin multimer distribution were studied in patients with type 2 diabetes. Design, patients and measurements The effect of 40 mg atorvastatin on HMW, medium molecular weight (MMW), and low molecular weight (LMW) isoforms of adiponectin were investigated in 75 patients (23 females; 52 males) with type 2 diabetes in an 8‐week‐long, placebo‐controlled and randomized study. Adiponectin multimeric isoforms were detected by Western blot analysis. Results After atorvastatin therapy the median serum concentration of HMW adiponectin increased significantly by 42·3% (1·68 vs. 2·39 µg/ml; P < 0·001), while concentrations of MMW adiponectin and LMW adiponectin significantly decreased by 20·8% and 23·2%, respectively (MMW: 3·31 vs. 2·62 µg/ml, P = 0·047; LMW: 0·56 vs. 0·43 µg/ml, P = 0·033). Median total adiponectin levels were not significantly altered by atorvastatin treatment (6·0 vs. 6·2 µg/ml, P = 0·898). Consequently, the HMW : total‐adiponectin ratio significantly increased by 25·0% (0·40 vs. 0·50; P = 0·013). Conclusions Atorvastatin therapy is associated with significant changes in adiponectin multimer distribution in patients with type 2 diabetes. Since total adiponectin levels were not affected by intervention, atorvastatin may shift adiponectin size towards the HMW form.
- Open Access
- 9 June 2009
- Published by American Diabetes Association in Diabetes
- Vol. 58 (9) , 2093-2099
Urinary Adiponectin Excretion
OBJECTIVE Markers reliably identifying vascular damage and risk in diabetic patients are rare, and reports on associations of serum adiponectin with macrovascular disease have been inconsistent. In contrast to existing data on serum adiponectin, this study assesses whether urinary adiponectin excretion might represent a more consistent vascular damage marker in type 2 diabetes. RESEARCH DESIGN AND METHODS Adiponectin distribution in human kidney biopsies was assessed by immunohistochemistry, and urinary adiponectin isoforms were characterized by Western blot analysis. Total urinary adiponectin excretion rate was measured in 156 patients with type 2 diabetes who had a history of diabetic nephropathy and 40 healthy control subjects using enzyme-linked immunosorbent assay. Atherosclerotic burden was assessed by common carotid artery intima-media-thickness (IMT). RESULTS A homogenous staining of adiponectin was found on the endothelial surface of glomerular capillaries and intrarenal arterioles in nondiabetic kidneys, whereas staining was decreased in diabetic nephropathy. Low-molecular adiponectin isoforms (∼30–70 kDa) were detected in urine by Western blot analysis. Urinary adiponectin was significantly increased in type 2 diabetes (7.68 ± 14.26 vs. control subjects: 2.91 ± 3.85 μg/g creatinine, P = 0.008). Among type 2 diabetic patients, adiponectinuria was associated with IMT (r = 0.479, P < 0.001) and proved to be a powerful independent predictor of IMT (β = 0.360, P < 0.001) in multivariable regression analyses. In a risk prediction model including variables of the UK Prospective Diabetes Study coronary heart disease risk engine urinary adiponectin, but not the albumin excretion rate, added significant value for the prediction of increased IMT (P = 0.007). CONCLUSIONS Quantification of urinary adiponectin excretion appears to be an independent indicator of vascular damage potentially identifying an increased risk for vascular events.
- 9 June 2009
- Published by American Diabetes Association in Diabetes
- Vol. 58 (9) , 2093-2099
Open AccessUrinary Adiponectin Excretion
OBJECTIVE Markers reliably identifying vascular damage and risk in diabetic patients are rare, and reports on associations of serum adiponectin with macrovascular disease have been inconsistent. In contrast to existing data on serum adiponectin, this study assesses whether urinary adiponectin excretion might represent a more consistent vascular damage marker in type 2 diabetes. RESEARCH DESIGN AND METHODS Adiponectin distribution in human kidney biopsies was assessed by immunohistochemistry, and urinary adiponectin isoforms were characterized by Western blot analysis. Total urinary adiponectin excretion rate was measured in 156 patients with type 2 diabetes who had a history of diabetic nephropathy and 40 healthy control subjects using enzyme-linked immunosorbent assay. Atherosclerotic burden was assessed by common carotid artery intima-media-thickness (IMT). RESULTS A homogenous staining of adiponectin was found on the endothelial surface of glomerular capillaries and intrarenal arterioles in nondiabetic kidneys, whereas staining was decreased in diabetic nephropathy. Low-molecular adiponectin isoforms (∼30–70 kDa) were detected in urine by Western blot analysis. Urinary adiponectin was significantly increased in type 2 diabetes (7.68 ± 14.26 vs. control subjects: 2.91 ± 3.85 μg/g creatinine, P = 0.008). Among type 2 diabetic patients, adiponectinuria was associated with IMT (r = 0.479, P < 0.001) and proved to be a powerful independent predictor of IMT (β = 0.360, P < 0.001) in multivariable regression analyses. In a risk prediction model including variables of the UK Prospective Diabetes Study coronary heart disease risk engine urinary adiponectin, but not the albumin excretion rate, added significant value for the prediction of increased IMT (P = 0.007). CONCLUSIONS Quantification of urinary adiponectin excretion appears to be an independent indicator of vascular damage potentially identifying an increased risk for vascular events.
- 1 June 2009
- Published by Elsevier in Atherosclerosis
- Vol. 206 (1) , 38-39
Retinol-binding protein 4 & atherosclerosis: Risk factor or innocent bystander?
- 1 June 2009
- Published by Elsevier in Atherosclerosis
- Vol. 206 (1) , 38-39
Retinol-binding protein 4 & atherosclerosis: Risk factor or innocent bystander?
- 14 December 2008
- Published by Springer Nature in Der Nephrologe
- Vol. 4 (1) , 61-62
Adiponektin
- Open Access
- 13 May 2008
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 29 (20) , 2579-2580
Adiponectin and prognostic outcome in patients with coronary artery disease: reply
The letter by Cesari et al.1 refers to yet unpublished data on the association between plasma adiponectin and prognostic outcome in patients with coronary heart disease (CHD). The authors exclusively focused on total adiponectin levels and did not consider its multimeric isoforms, such as the high-molecular weight isoform. In accordance with our study,2 adiponectin levels did not yield additional predictive value for secondary cardiovascular disease events in addition to traditional cardiovascular risk factors after appropriate adjustment for covariates and consequently may not be regarded as an independent biomarker for future risk in patients with prevalent CHD. However, we like to emphasize distinct differences regarding patient selection and design of the two studies resulting in important consequences for data interpretation.
- 13 May 2008
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 29 (20) , 2579-2580
Open AccessAdiponectin and prognostic outcome in patients with coronary artery disease: reply
The letter by Cesari et al.1 refers to yet unpublished data on the association between plasma adiponectin and prognostic outcome in patients with coronary heart disease (CHD). The authors exclusively focused on total adiponectin levels and did not consider its multimeric isoforms, such as the high-molecular weight isoform. In accordance with our study,2 adiponectin levels did not yield additional predictive value for secondary cardiovascular disease events in addition to traditional cardiovascular risk factors after appropriate adjustment for covariates and consequently may not be regarded as an independent biomarker for future risk in patients with prevalent CHD. However, we like to emphasize distinct differences regarding patient selection and design of the two studies resulting in important consequences for data interpretation.
- 1 May 2008
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 8 (3) , 289-299
Retinol-binding protein-4 in experimental and clinical metabolic disease
Retinol-binding protein-4 (RBP4), a 21-kDa protein synthesized in the liver and adipose tissue, has recently been described as a murine adipokine involved in the development of insulin resistance. The expression of the gene encoding RBP4 was increased in the adipose tissue, but not in the liver, of insulin-resistant adipose GLUT4(-/-) mice and five other mouse models of obesity and insulin resistance. In addition, intraperitoneal injection or transgenic overexpression of RBP4 in mice induced insulin resistance. While experimental clinical approaches (mostly applying clamp techniques) in humans confirmed correlations of RBP4 with insulin resistance, studies in larger groups out of clinical routine failed to demonstrate a connection with alternative measures of insulin sensitivity. Yet, significant associations of RBP4 with atherogenic lipids were found and a focus of future studies should be the influence on atherosclerosis and related complications. Based on current data, the function of RBP4 as an adipokine exerting metabolic effects in glucose metabolism in humans remains uncertain and might be restricted to rodent models.
- 1 May 2008
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 8 (3) , 289-299
Retinol-binding protein-4 in experimental and clinical metabolic disease
Retinol-binding protein-4 (RBP4), a 21-kDa protein synthesized in the liver and adipose tissue, has recently been described as a murine adipokine involved in the development of insulin resistance. The expression of the gene encoding RBP4 was increased in the adipose tissue, but not in the liver, of insulin-resistant adipose GLUT4(-/-) mice and five other mouse models of obesity and insulin resistance. In addition, intraperitoneal injection or transgenic overexpression of RBP4 in mice induced insulin resistance. While experimental clinical approaches (mostly applying clamp techniques) in humans confirmed correlations of RBP4 with insulin resistance, studies in larger groups out of clinical routine failed to demonstrate a connection with alternative measures of insulin sensitivity. Yet, significant associations of RBP4 with atherogenic lipids were found and a focus of future studies should be the influence on atherosclerosis and related complications. Based on current data, the function of RBP4 as an adipokine exerting metabolic effects in glucose metabolism in humans remains uncertain and might be restricted to rodent models.
- Open Access
- 7 December 2007
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 29 (10) , 1307-1315
Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease
Adiponectin is closely related to atherogenic dyslipidaemia and may be a clinical important mediator of recurrent coronary heart disease (CHD). However, studies with emphasis on secondary disease prevention are rare. We report data from a prospective study investigating the prognostic value of adiponectin, its high-molecular weight (HMW) form, and of markers of lipid metabolism in patients after their first acute CHD event. We measured baseline total- and HMW-adiponectin in 1051 patients aged 30–70 years with incident CHD and a prospective follow-up was conducted [median: 56.6 months (interquartile range: 53.2; 57.5)]. During this period, 95 patients (incidence: 22.3/1000 patient years) experienced a secondary cardiovascular disease (CVD) event. After adjustment by Cox proportional hazard models, neither total- nor HMW-adiponectin was associated with secondary CVD events. In contrast, LDL-cholesterol and markers of atherogenic dyslipidaemia were independently associated with secondary CVD events (relative risk per unit increase: LDL-cholesterol: 1.54; 95%CI 1.18–2.01; P = 0.001, triglycerides: 1.58; 95%CI 1.31–1.90; P < 0.0001 and HDL-cholesterol: 0.34; 95%CI 0.14–0.79; P = 0.01). Measurement of total- and HMW-adiponectin may add no significant value to risk stratifications in patients with incident CHD. In contrast, approaching atherogenic dyslipidaemia may represent a promising target in secondary prevention programs for high-risk patients.
- 7 December 2007
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 29 (10) , 1307-1315
Open AccessAtherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease
Adiponectin is closely related to atherogenic dyslipidaemia and may be a clinical important mediator of recurrent coronary heart disease (CHD). However, studies with emphasis on secondary disease prevention are rare. We report data from a prospective study investigating the prognostic value of adiponectin, its high-molecular weight (HMW) form, and of markers of lipid metabolism in patients after their first acute CHD event. We measured baseline total- and HMW-adiponectin in 1051 patients aged 30–70 years with incident CHD and a prospective follow-up was conducted [median: 56.6 months (interquartile range: 53.2; 57.5)]. During this period, 95 patients (incidence: 22.3/1000 patient years) experienced a secondary cardiovascular disease (CVD) event. After adjustment by Cox proportional hazard models, neither total- nor HMW-adiponectin was associated with secondary CVD events. In contrast, LDL-cholesterol and markers of atherogenic dyslipidaemia were independently associated with secondary CVD events (relative risk per unit increase: LDL-cholesterol: 1.54; 95%CI 1.18–2.01; P = 0.001, triglycerides: 1.58; 95%CI 1.31–1.90; P < 0.0001 and HDL-cholesterol: 0.34; 95%CI 0.14–0.79; P = 0.01). Measurement of total- and HMW-adiponectin may add no significant value to risk stratifications in patients with incident CHD. In contrast, approaching atherogenic dyslipidaemia may represent a promising target in secondary prevention programs for high-risk patients.
- 16 November 2007
- Published by Elsevier in Atherosclerosis
- Vol. 199 (1) , 123-128
High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men
- 16 November 2007
- Published by Elsevier in Atherosclerosis
- Vol. 199 (1) , 123-128
High-molecular weight adiponectin is independently associated with the extent of coronary artery disease in men
- 18 July 2007
- Published by Springer Nature in Diabetologia
- Vol. 50 (9) , 1930-1937
Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease
Retinol-binding protein 4 (RBP4) has recently been reported to be associated with insulin resistance and the metabolic syndrome. This study tested the hypothesis that RBP4 is a marker of insulin resistance and the metabolic syndrome in patients with type 2 diabetes or coronary artery disease (CAD) or in non-diabetic control subjects without CAD.
- 18 July 2007
- Published by Springer Nature in Diabetologia
- Vol. 50 (9) , 1930-1937
Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease
Retinol-binding protein 4 (RBP4) has recently been reported to be associated with insulin resistance and the metabolic syndrome. This study tested the hypothesis that RBP4 is a marker of insulin resistance and the metabolic syndrome in patients with type 2 diabetes or coronary artery disease (CAD) or in non-diabetic control subjects without CAD.